Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Stock Report

Market Cap: US$1.6b

Syndax Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:SNDX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Feb 26SellUS$71,705Keith GoldanIndividual3,410US$21.03
09 Feb 26SellUS$360,819Michael MetzgerIndividual17,159US$21.03
06 Feb 26SellUS$152,835Michael MetzgerIndividual7,412US$20.62
06 Feb 26SellUS$42,931Keith GoldanIndividual2,082US$20.62
16 Jul 25SellUS$69,953Michael MetzgerIndividual7,534US$9.29
16 Jul 25SellUS$12,033Keith GoldanIndividual1,296US$9.29

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SNDX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,526,4361.51%
Hedge Funds8,050,9597.95%
Institutions91,746,19390.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 76.89% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.32%
BlackRock, Inc.
8,254,358US$148.7m0.19%no data
9.09%
Kynam Capital Management, LP
8,050,959US$145.1m0%10.2%
5.38%
The Goldman Sachs Group, Inc.
4,770,090US$86.0m-12.3%0.02%
5%
State Street Global Advisors, Inc.
4,430,076US$79.8m-3.62%no data
4.31%
Vanguard Capital Management, LLC
3,822,579US$68.9m0%no data
4.27%
Deerfield Management Company, L.P.
3,779,900US$68.1m0%0.93%
3.29%
Bank of America Corporation
2,912,343US$52.5m-13.2%0.01%
3.26%
Eversept Partners, L.P.
2,885,622US$52.0m-12.9%3.75%
2.82%
Kingdon Capital Management, L.L.C.
2,500,000US$45.0m6.38%6.94%
2.66%
Hood River Capital Management LLC
2,354,285US$42.4m1.63%0.33%
2.43%
Geode Capital Management, LLC
2,157,058US$38.9m3.16%no data
2.39%
Franklin Resources, Inc.
2,120,281US$38.2m-11.4%0.01%
2.24%
Point72 Asset Management, L.P.
1,985,547US$35.8m-59.3%0.06%
2.09%
Elmind Capital, L.P.
1,855,000US$33.4m0%10.6%
1.96%
Vanguard Portfolio Management, LLC
1,737,141US$31.3m0%no data
1.96%
BNPP Asset Management Holding
1,732,541US$31.2m25.9%0.03%
1.95%
Soleus Capital Management, L.P.
1,726,908US$31.1m-23.1%1.18%
1.81%
D. E. Shaw & Co., L.P.
1,601,896US$28.9m31.4%0.02%
1.78%
Two Sigma Investments, LP
1,579,596US$28.5m37.7%0.02%
1.63%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,445,182US$26.0m0.92%0.01%
1.51%
MPM BioImpact LLC
1,340,733US$24.2m0.23%1.79%
1.49%
Aisling Capital Management LP
1,316,806US$23.7m0%5.63%
1.47%
UBS Asset Management AG
1,303,459US$23.5m51.8%no data
1.41%
Woodline Partners LP
1,250,760US$22.5m0.01%0.08%
1.37%
StemPoint Capital LP
1,215,743US$21.9m-9.23%4.44%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/05 16:29
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syndax Pharmaceuticals, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Jason ZemanskyBofA Global Research